Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial

Next Previous
Trial Profile

Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefitolimod (Primary) ; Teropavimab (Primary) ; Zinlirvimab (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TITAN

    • Most Recent Events

    • 01 Oct 2023 Results published in the Nature Medicine
    • 22 May 2023 Status changed from active, no longer recruiting to completed.
    • 22 Feb 2023 Primary endpoint has not been met. (time to loss of virological control (plasma HIV-RNA 1,000 c/mL for 4 weeks or confirmed 100,000 c/mL), in the combination of LEFI and bNAbs vs. bNAbs)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top